Virios Therapeutics (VIRI) News Today → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free VIRI Stock Alerts $0.41 +0.02 (+5.17%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 1:24 AM | americanbankingnews.comHC Wainwright Analysts Raise Earnings Estimates for Virios Therapeutics, Inc. (NASDAQ:VIRI)May 15 at 5:26 AM | americanbankingnews.comBrokers Set Expectations for Virios Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:VIRI)May 13 at 3:39 PM | markets.businessinsider.comMaintaining Hold on Virios Therapeutics Amid Financial Strains and Clinical Development RisksMay 13 at 3:39 PM | finance.yahoo.comVIRI: Results for Phase 2 Long COVID Trial Expected in 2H24…May 13 at 3:39 PM | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call TranscriptMay 12, 2024 | uk.investing.comEarnings call: Virios Therapeutics reports on Q1 2024 progressMay 11, 2024 | msn.comVirios Reveals Figures, Corporate UpdateMay 9, 2024 | msn.comVIRI Stock Earnings: Virios Therapeutics Misses EPS for Q1 2024May 9, 2024 | finanznachrichten.deVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | americanbankingnews.comVirios Therapeutics (VIRI) Scheduled to Post Earnings on ThursdayMay 2, 2024 | globenewswire.comVirios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024April 14, 2024 | finance.yahoo.comVirios Therapeutics, Inc. (VIRI)March 28, 2024 | investing.comVirios Therapeutics seeks global patent for antiviral comboMarch 26, 2024 | globenewswire.comVirios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDFebruary 29, 2024 | investing.comVirios Therapeutics announces salary cuts for employees and boardFebruary 29, 2024 | markets.businessinsider.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | markets.businessinsider.comVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesFebruary 28, 2024 | globenewswire.comVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesFebruary 27, 2024 | investing.comVirios Therapeutics Llc (VIRI)February 25, 2024 | msn.comVirios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08February 9, 2024 | morningstar.comVirios Therapeutics Inc Ordinary Shares VIRIFebruary 7, 2024 | finance.yahoo.comVIRI: Moving IMC-2 into Phase 2 Program in Long COVIDFebruary 6, 2024 | finance.yahoo.comFibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research NesterJanuary 23, 2024 | benzinga.comVirios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and DatesJanuary 22, 2024 | finanznachrichten.deVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDJanuary 22, 2024 | finance.yahoo.comVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDJanuary 2, 2024 | markets.businessinsider.comVirios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2January 2, 2024 | finance.yahoo.comVirios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDDecember 7, 2023 | morningstar.comVirios Therapeutics Inc Ordinary SharesNovember 14, 2023 | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | finance.yahoo.comVIRI: Provides Overview of Phase 3 Program in FibromyalgiaNovember 13, 2023 | msn.comVirios Therapeutics GAAP EPS of -$0.06 beats by $0.04November 13, 2023 | finance.yahoo.comVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | msn.comSenti stock soars 175% on Chinese development deal for cancer drugNovember 6, 2023 | finance.yahoo.comVirios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023October 12, 2023 | finance.yahoo.comVirios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023September 18, 2023 | finance.yahoo.comVirios Therapeutics Announces Termination of At-The-Market Sales AgreementSeptember 12, 2023 | finance.yahoo.comVirios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023August 15, 2023 | finance.yahoo.comVIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024…August 14, 2023 | benzinga.comWhat In The World Is Going On With Virios Therapeutics (VIRI) Stock?August 14, 2023 | marketwatch.comVirios Therapeutics Shares Rise 11% After Halt to At-The-Market Offering SalesAugust 14, 2023 | finance.yahoo.comVirios Therapeutics Announces Halt to At-The-Market Offering SalesAugust 12, 2023 | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call TranscriptAugust 10, 2023 | finance.yahoo.comVirios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | benzinga.comVirios Therapeutics's Earnings OutlookAugust 9, 2023 | finance.yahoo.comVirios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for FibromyalgiaAugust 3, 2023 | finance.yahoo.comVirios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. VIRI Media Mentions By Week VIRI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIRI News Sentiment▼0.630.54▲Average Medical News Sentiment VIRI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIRI Articles This Week▼141▲VIRI Articles Average Week Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cadrenal Therapeutics News Trevena News Bionomics News NuCana News Biofrontera News Cyclerion Therapeutics News Vaccinex News eFFECTOR Therapeutics News Hepion Pharmaceuticals News Universe Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIRI) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
